Marshall Wace North America
PLRX icon

Marshall Wace North America’s Pliant Therapeutics PLRX Stock Holding History

Marshall Wace North America’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-38,825
Closed -$1.26M – 1418
2020
Q2 		$1.26M Buy
+38,825
New +$1.03M 0.01% 701

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Harvard Management Company
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Marshall Wace North America's PLRX Position: Q3 2020 in Review

Marshall Wace North America sold out of Pliant Therapeutics (PLRX) in Q3 2020, closing a stake of 38,825 shares — an estimated $1.26M sold.

Marshall Wace North America first reported a position in PLRX in Q2 2020 and held it in 1 quarter. The position peaked at $1.26M in Q2 2020. 55 funds tracked by Wall St. Rank hold PLRX as of Q3 2020.

  • Marshall Wace North America reported no remaining Pliant Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Marshall Wace North America sold 38,825 Pliant Therapeutics shares in Q3 2020, an estimated $1.26M.
  • Marshall Wace North America first reported a position in Pliant Therapeutics in Q2 2020 and held it in 1 quarter.
  • Marshall Wace North America's Pliant Therapeutics position peaked at $1.26M in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2020.

Based on Marshall Wace North America's 13F filing for Q3 2020, filed 16 Nov 2020.